Prostate Cancer and Bone Metastasis Evaluation

Primary Laboratory Assessment

The European Association of Urology recommends serum prostate-specific antigen (PSA) as the cornerstone laboratory test for prostate cancer evaluation and risk stratification, with PSA levels directly informing risk classification and guiding subsequent imaging decisions 1, 2
The American Urological Association suggests that alkaline phosphatase (ALP) is significantly elevated in patients with prostate cancer and bone metastases compared to those without metastases, and bone-specific alkaline phosphatase (B-ALP) is a more sensitive and specific marker than total ALP for bone turnover and metastases 3

The American College of Radiology recommends that patients with PSA >20 ng/mL or Gleason ≥8 or Stage ≥T3 should undergo bone scan regardless of symptoms, and obtain baseline ALP and B-ALP levels for prognostic information 4, 2, 5
The European Urology guidelines suggest that for intermediate-risk patients, consider bone scan if multiple adverse features are present or ALP is elevated 1, 2

The Journal of the American College of Radiology states that PSA >20 ng/mL is an indication for bone scan regardless of other factors, and ALP correlates better with abnormal bone scans than PSA levels alone 4, 2
The Cancer Treatment Reviews journal notes that serial monitoring of B-ALP can track disease progression and treatment response 3

The European Urology guidelines warn that androgen deprivation therapy (ADT) can alter bone biomarker levels independent of metastases, potentially causing false elevations, and denosumab and bisphosphonates may alter biomarker levels despite presence of bone metastases, complicating interpretation 3
The American College of Radiology recommends that any patient with bone pain should undergo bone scintigraphy regardless of PSA or ALP levels, and symptoms override risk stratification algorithms 4

The European Urology journal suggests that PSMA PET/CT demonstrates superior accuracy (92% vs 65% for conventional imaging) but is not yet universally accessible 1, 2

The European Association of Urology (EAU) guidelines recommend performing PSMA PET/CT for metastatic screening in high-risk localized disease and locally advanced disease (strong recommendation) 6
The European Association of Urology (EAU) guidelines suggest using PSMA PET/CT to increase accuracy even in intermediate-risk disease (weak recommendation) 6

The American College of Radiology recommends using PSMA PET/CT as a single comprehensive study for high-risk disease (PSA >20 ng/mL, Gleason ≥8, or stage ≥T3) 6
The American College of Radiology recommends using PSMA PET/CT for biochemical recurrence after definitive treatment 7
The American College of Radiology recommends using PSMA PET/CT for castration-resistant prostate cancer 7

PSMA PET/CT has a sensitivity of 87% and specificity of 97% for bone metastases detection (per-patient basis) 8
Bone scintigraphy has a sensitivity of 79% and specificity of 82% for bone metastases detection 9 10
MRI has a sensitivity of 95% and specificity of 96% for bone metastases detection (but limited to imaged field) 8
PSMA PET/CT has a lymph node sensitivity of 77% and specificity of 97% after extended lymph node dissection 6

PSMA PET/CT delivers significantly less radiation (8.4 mSv) compared to conventional CT + bone scan (19.2 mSv) 6

PSMA PET/CT changed management in 28% of patients versus 15% with conventional imaging (p=0.08) in the proPSMA trial 6
Earlier detection of oligometastatic disease by PSMA PET/CT allows targeted salvage therapy rather than systemic palliative treatment 11

The proPSMA trial demonstrated that PSMA PET/CT has 92% accuracy versus 65% for conventional imaging (CT + bone scan) 6
PSMA PET/CT showed a sensitivity of 85% versus 38% for conventional imaging 6
PSMA PET/CT showed a specificity of 98% versus 91% for conventional imaging 6
PSMA PET/CT had fewer equivocal findings: 7% versus 23% for conventional imaging 6